Price History

Hover for the daily close. The dotted line marks the period open.

Compare SILO with… →

SILO Key Statistics

As of Sep 4, 2026

Trading

Open: $2.45
Previous Close: $2.45
Day's Range: 2.21–2.50
52-Week Range: 2.21–15.15
Volume: 35.50K
Beta: 0.75

Valuation

Market Cap: $4.21M
P/E Ratio: unprofitable
P/S ratio: 77.81
EPS (ttm): −3.74

Financials (FY)

Revenue (FY): $72.10K+0.00%
Net Income (FY): −$4.23M
Profit margin: 0.00%
Shares Outstanding: 1.75M
1-Year Return: −73.38%

Dividend and dates

Avg Volume: 193.42K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SILO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−59.14%−53.01%−57.14%−38.19%−61.80%−52.94%

202120222023202420252026*

Year	Return
2026 (partial year)	−52.94%
2025	−61.80%
2024	−38.19%
2023	−57.14%
2022	−53.01%
2021	−59.14%

As of September 4, 2026.

SILO Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$72.10K	−$4.23M	−5863.5%
2024	$72.10K	−$4.39M	−6092.6%
2023	$72.10K	−$3.70M	−5132.6%
2022	$72.10K	−$3.91M	−5420.9%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$72.10K	$27.81K	−$4.28M	−$4.23M	−5863.5%
2024	$72.10K	$66.26K	−$4.71M	−$4.39M	−6092.6%
2023	$72.10K	$66.26K	−$3.86M	−$3.70M	−5132.6%
2022	$72.10K	$66.26K	−$3.65M	−$3.91M	−5420.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SILO Valuation vs Biotechnology Median

Median of 656 stocks

Metric	SILO	Biotechnology median	vs median
P/S ratio	77.81	15.26	5.1x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Silo Pharma, Inc. (SILO) is capitalised at $4.21M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 3.

The 52-week range on file runs from $2.21 to $15.15. SILO last closed at $2.40 on September 4, 2026. That is −$0.05 (−2.04%) against the previous close. The latest close sits 8.84% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $72.10K. Against the prior fiscal year total of $72.10K, that is a change of 0.00%. The same year closed with a net loss of $4.23M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −3.74.

Across the 4 fiscal years on file, revenue moves from $72.10K in 2022 to $72.10K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 77.81 times revenue. On price-to-sales that is 5.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −73.38%. Across 5 years the annualized return works out at −55.23%. The reported beta is 0.75. Daily returns over the trailing 5 years annualize to a volatility of 1,871.46%.

Growth & Income

No dividend is on file for SILO.

Across the complete calendar years on file, 2024 returned −38.19% and 2025 returned −61.80%. Of the 5 complete calendar years on file, 0 finished higher. So far in 2026 the price is −52.94%.

Peer Comparison

Silo Pharma, Inc. (SILO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Silo Pharma, Inc.	SILO	$4.21M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Silo Pharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Silo Pharma, Inc.

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Visit website →

Silo Pharma, Inc. (SILO) Stock Analysis